Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma

Podcast

CancerNetwork®’s podcast features an interview with the chairman and CEO of Enveric Biosciences, David Johnson, to discuss the latest in their development of endocannabinoid products.

In this episode, CancerNetwork® sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson thoroughly discussed the background of the biosciences company and detailed the endocannabinoid products Enveric is developing to positively impact quality of life for patients with glioblastoma and other cancers.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast anywhere podcasts are available.

Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Related Content
A Multifaceted Approach to Managing Cancer-Related Anxiety and Depression

A Multifaceted Approach to Managing Cancer-Related Anxiety and Depression

Boris M. Kiselev, MD
August 27th 2025
Article

Boris M. Kiselev, MD, explores evidence-based interventions for managing cancer-related anxiety and depression.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Ariana Pelosci
August 25th 2025
Article

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 15th 2025
Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.